Smooth muscle antibodies (S.M.A.) were found in the sera of 81% of 126 patients over 10 years old with seropositive infectious mononucleosis tested within one month of onset. In 27 patients presenting clinically with infectious mononucleosis but having negative Paul-Bunneil tests the incidence of S.M.A. was 44%. In children 10 years of age or less in these two categories S.M.A. were present in 75% and 25% respectively, while in children of similar age not suspected of having infectious mononucleosis the incidence of S.M.A. was 10%. Among 45 adults with past histories of seropositive infectious mononucleosis more than one year before the incidence of S.M.A. was 33%, in contrast to 14% in 98 subjects with a negative history for infectious mononucleosis.
Introduction
Smooth muscle autoatibodies (S.M.A.) were first reported in the sera of patients with chronic active hepatitis (Johnson et al., 1965) and later assigned to a group of persistent, chiefly IgG, antibody markers of the autoimmune forms of chronic hepatitis (Doniach and Walker, 1969) . S.M.A. have since proved to be more widely distributed, occuring early (predominantly at IgM) in acute viral hepatitis (Farrow et al., 1970) and, in ithe one study reported so far, in a majority of cases of malignant disease (Whitchouse and Holborow, 1971 ).
We have also found S.M.A. in the sera of some subjects apparently healthy at the time of testing and in certain patients with diseases other than those mentioned.
Recently we have noted S.M.A. in sera from patients with infectious mononucleosis (Holborow, 1972 a, b) . This paper reports a study of the occurrence of S.M.A. during -the acute illness of infectious mononucleosis, during follow-up after recovery, and in subjects with and without a past history of clinical infec,tious mononucleosis. at 1/10 dilution as previously described (Farrow et al., 1970) . Fluorescein isothiocyanate (FITC) conjugates of Wellcome sheep antihuman immunoglobulin, anti-IgG, and antiIgM were used at dilutions (usually 1/32) which gave minimal nonspecific staining by indirect imunofluorescence with normal human sera.
Sections were examined with a Reichert Zetopan microscope fitted with an iodine quartz lamp, Balzer FITC-3 interference filter with cut-off to 0-3% transmission at 500/.m and a Wratten 2B gela-tin barrier filter, a dry 40x objective (NA 0-9), and 6x eye-pieces. The intensity of staining in three areas-smooth muscle fibres in the gastric mucosa, musculais mucosae, and renal arteriolar walls-was scored for each area as 0 (negative), 1 (doubtful), 2 (definite), or 3 (strong). Sera scoring 8-9 were classed as "stong," 5-7 as "moderate+," and less than 5 as negative.
Patients
The following groups were studied. (Farrow et al., 1970 jects with a history of Paul-Bunnel-positive infectious mononucleosis more thn one year before testing (group 4) the incidence of S.MA was higher (33%) than the 14% found in a group of simnilar age distribution (group 5) with negative histories. The figure for cord blood samples was similar (8/66 positives, or 12%).
The question nest arises why subjects with a negative history nevertheless show an appreciable incidence (14%) of S.M.A.
It is known (Henle and Henle, 1967) that during adolescence and early adult life the ncidence of antibody to E.B.
virus rises steadily. Despite their negative history, theefore, the subjects in group 5 may have had undiagnosed clinical or unnoticed subclinical infecdous mononucleosis which could have left a popor of them with persistent S.M.A.
To investigate this possi'blity we tested a group of children 10 years old or less for E.B. virus antibody and for S.M.A.
The incidence of E.B. virus antbody in these children (group 3) was 45% and the incidence of S.M.A. 10%, but no correlation between the two was evident. (Ajdukiewicz et al., 1972) . The importance of extrinsic agents such as infection rather than genetic factors in determining the presence and lack of sex selectivity of S.M.A. was pointed out by Hooper et al. (1972) , who drew attention to the contrast between S.M.A. and many other autoantibodies in these resipects.
The role of hepatic damage in S.M.A. production requires further consideration in the light of the presen-t findings. The presence of S.M.A. is linked in the literature with certain forms of liver disease, though Whitehouse and Holborow (1972) (Farrow et al., 1971) for several cell types that S.M.A.-positive sera may react specifically with a subcellular microfilamentous network associated with 'the cell surface, and it seems likely that this explains the polygonal pattern of liver staining seen with some of thenm It has been shown, however, that absorption with crude actomyosin extracted from human myometrium effectively renoves not only the antibodies in human sera which stain smooth muscle fibres but also the ability that somne such sera have to produce polygonal and glomerular staining. It was suggested, therefore (Holborow, 1972 a, b) , that in certain viral infections antigenic modification of contractile proteins in the infected cells occurs which leads to production of autoantibodies recognizable by their specific reactivity with smooth muscle. In infectious mononucleosis such a process would presumably involve liver cells, but there is nothing liver-specific about cellular contractile proteins, and similar effects of virus in other cells-for example, *the atypical lymphocytes-could equally contribute to production of polygonal and glomerular auitoantibodies.
Our finding here tha-t while most infectious mononucleosis sera give smooth muscle sta iing only some give polygonal or glomerular staining or both points to the likelihood that more than one antigenic specificty is involved in this postulated process of autoinimunization. Our experiments now in progress are ivestigating the staining patterns produced by antisera raised in rabbits against the various contractile protein subunits of smooth muscle; it is hoped to obtain informaition which will help identification of the different antigenic cellular components capable of giving rise to smooth ,'nuscle autoantibodies in human disease.
